{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T08:09:34Z","timestamp":1778573374066,"version":"3.51.4"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T00:00:00Z","timestamp":1770940800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003625","name":"Ministry of Health and Welfare","doi-asserted-by":"publisher","award":["HA 23C0144"],"award-info":[{"award-number":["HA 23C0144"]}],"id":[{"id":"10.13039\/501100003625","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003625","name":"Ministry of Health and Welfare","doi-asserted-by":"publisher","award":["RS- 2024-00343001"],"award-info":[{"award-number":["RS- 2024-00343001"]}],"id":[{"id":"10.13039\/501100003625","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.breast.2026.104738","type":"journal-article","created":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T00:19:58Z","timestamp":1771028398000},"page":"104738","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Late distant recurrence prediction model in premenopausal women with ER-positive\/HER 2-negative breast cancer: A multicenter retrospective study"],"prefix":"10.1016","volume":"86","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8915-8944","authenticated-orcid":false,"given":"Dong Seung","family":"Shin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janghee","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eunhye","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dasom","family":"Noh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jong-Ho","family":"Cheun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun-Hee","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yeongyeong","family":"Son","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soong June","family":"Bae","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sunyoung","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Han-Byoel","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jai Min","family":"Ryu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8778-9686","authenticated-orcid":false,"given":"Sung Gwe","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.breast.2026.104738_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.106535","article-title":"Breast cancer: biology, biomarkers, and treatments","volume":"84","author":"Barzaman","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.breast.2026.104738_bib2","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1200\/JCO.2012.46.1574","article-title":"Patterns of recurrence and outcome according to breast cancer subtypes in lymph node-negative disease: results from international breast cancer study group trials VIII and IX","volume":"31","author":"Metzger-Filho","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2026.104738_bib3","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1056\/NEJMoa1701830","article-title":"20-Year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years","volume":"377","author":"Pan","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.breast.2026.104738_bib4","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S0140-6736(12)61963-1","article-title":"Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial","volume":"381","author":"Davies","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.breast.2026.104738_bib5","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1200\/jco.2013.31.18_suppl.5","article-title":"aTTom: long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer","volume":"31","author":"Gray","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2026.104738_bib6","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1803164","article-title":"Tailoring adjuvant endocrine therapy for premenopausal breast cancer","volume":"379","author":"Francis","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.breast.2026.104738_bib7","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/S1470-2045(15)00049-2","article-title":"Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials","volume":"16","author":"Bernhard","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.breast.2026.104738_bib8","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/S0140-6736(15)01169-1","article-title":"Patient-reported outcomes with anastrozole versus tamoxifen for postmenopausal patients with ductal carcinoma in situ treated with lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial","volume":"387","author":"Ganz","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.breast.2026.104738_bib9","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1200\/JCO.24.01131","article-title":"Explaining the relationships between age, endocrine therapy persistence, and risk of recurrence in hormone receptor-positive early breast cancer: a nationwide cohort study","volume":"43","author":"Dumas","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2026.104738_bib10","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1200\/JCO.2017.76.4258","article-title":"Integration of clinical variables for the prediction of late distant recurrence in patients with Estrogen receptor-positive breast cancer treated with 5 years of endocrine therapy: CTS5","volume":"36","author":"Dowsett","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2026.104738_bib11","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.691277","article-title":"Validation of the clinical treatment score post-five years in breast cancer patients for predicting late distant recurrence: a single-center investigation in Korea","volume":"11","author":"Lee","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.breast.2026.104738_bib12","article-title":"Clinical treatment score Post-5 years as a tool for risk estimation of late recurrence in Thai patients with estrogen-receptor-positive, early breast cancer: a validation study","volume":"17","author":"Dejthevaporn","year":"2023","journal-title":"Breast Cancer"},{"key":"10.1016\/j.breast.2026.104738_bib13","article-title":"Validation of clinical treatment score post-5 years (CTS5) risk stratification in premenopausal breast cancer patients and Ki-67 labelling index","volume":"10","author":"Lee","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.breast.2026.104738_bib14","doi-asserted-by":"crossref","first-page":"e53","DOI":"10.1016\/j.clbc.2020.06.008","article-title":"Validation of CTS5 on a retrospective cohort of real-life Pre- and postmenopausal patients diagnosed with estrogen receptor-positive breast cancers: is it prognostic?","volume":"21","author":"Villasco","year":"2021","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.breast.2026.104738_bib15","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1097\/COC.0000000000001080","article-title":"Validation of CTS5 model in large-scale breast cancer population and combination of CTS5 and Ki-67 status to develop a novel nomogram for prognosis prediction","volume":"47","author":"Ning","year":"2024","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.breast.2026.104738_bib16","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s10549-020-06013-6","article-title":"Clinical validity of clinical treatment score 5 (CTS5) for estimating risk of late recurrence in unselected, non-trial patients with early oestrogen receptor-positive breast cancer","volume":"186","author":"Richman","year":"2021","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.breast.2026.104738_bib17","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S0140-6736(25)01013-X","article-title":"Extending the duration of endocrine treatment for early breast cancer: patient-level meta-analysis of 12 randomised trials of aromatase inhibitors in 22 031 postmenopausal women already treated with at least 5 years of endocrine therapy","volume":"406","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.breast.2026.104738_bib18","series-title":"AJCC cancer staging manual","author":"Amin","year":"2017"},{"key":"10.1016\/j.breast.2026.104738_bib19","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0167-9473(98)00096-6","article-title":"An application of change point methods in studying the effect of age on survival in breast cancer","volume":"30","author":"Contal","year":"1999","journal-title":"Comput Stat Data Anal"},{"key":"10.1016\/j.breast.2026.104738_bib20","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1158\/1078-0432.CCR-18-2782","article-title":"Impact of breast cancer subtypes on prognosis of women with operable invasive breast cancer: a population-based study using SEER database","volume":"25","author":"Hwang","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.breast.2026.104738_bib21","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3121\/cmr.2008.825","article-title":"Breast cancer subtypes based on ER\/PR and Her2 expression: comparison of clinicopathologic features and survival","volume":"7","author":"Onitilo","year":"2009","journal-title":"Clin Med Res"},{"key":"10.1016\/j.breast.2026.104738_bib22","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1200\/JCO.2010.32.3550","article-title":"Breast cancer adjuvant therapy: time to consider its time-dependent effects","volume":"29","author":"Jatoi","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2026.104738_bib23","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1200\/JCO.2014.57.2461","article-title":"Comparison of breast cancer recurrence and outcome patterns between patients treated from 1986 to 1992 and from 2004 to 2008","volume":"33","author":"Cossetti","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2026.104738_bib24","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1002\/ijc.31950","article-title":"Breast cancer-specific survival by clinical subtype after 7 years follow-up of young and elderly women in a nationwide cohort","volume":"144","author":"Johansson","year":"2019","journal-title":"Int J Cancer"},{"key":"10.1016\/j.breast.2026.104738_bib25","doi-asserted-by":"crossref","first-page":"3308","DOI":"10.1200\/JCO.2015.65.8013","article-title":"Subtype-dependent relationship between young age at diagnosis and breast cancer survival","volume":"34","author":"Partridge","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2026.104738_bib26","doi-asserted-by":"crossref","first-page":"2959","DOI":"10.1038\/bjc.2013.671","article-title":"The EndoPredict score provides prognostic information on late distant metastases in ER+\/HER2- breast cancer patients","volume":"109","author":"Dubsky","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1016\/j.breast.2026.104738_bib27","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1093\/annonc\/mdz289","article-title":"Breast cancer index and prediction of benefit from extended endocrine therapy in breast cancer patients treated in the adjuvant Tamoxifen-To offer more? (aTTom) trial","volume":"30","author":"Bartlett","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2026.104738_bib28","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1111\/j.1349-7006.2011.02047.x","article-title":"Genetic and environmental predictors, endogenous hormones and growth factors, and risk of estrogen receptor-positive breast cancer in Japanese women","volume":"102","author":"Yoshimoto","year":"2011","journal-title":"Cancer Sci"},{"key":"10.1016\/j.breast.2026.104738_bib29","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1200\/JCO.2013.49.4062","article-title":"Menopausal status should be taken into consideration for patients with luminal a breast cancer in terms of the effect of differential biology on prognosis","volume":"31","author":"Yamamoto","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2026.104738_bib30","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1007\/s12282-015-0649-0","article-title":"Clinicopathological factors predicting early and late distant recurrence in estrogen receptor-positive, HER2-negative breast cancer","volume":"23","author":"Yamashita","year":"2016","journal-title":"Breast Cancer"},{"key":"10.1016\/j.breast.2026.104738_bib31","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s10549-018-4892-x","article-title":"Chronologically changing patterns in the survival of Korean patients with breast cancer and related clinical factors: a nationwide registry-based study","volume":"172","author":"Lee","year":"2018","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.breast.2026.104738_bib32","article-title":"Improvement of survival in Korean breast cancer patients over a 14-year period: a large-scale single-center study","volume":"17","author":"Kim","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.breast.2026.104738_bib33","doi-asserted-by":"crossref","first-page":"4050","DOI":"10.1200\/JCO.2002.02.054","article-title":"Quality of life of women with recurrent breast cancer and their family members","volume":"20","author":"Northouse","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2026.104738_bib34","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1158\/1078-0432.CCR-20-2737","article-title":"Breast cancer index predicts extended endocrine benefit to individualize selection of patients with HR(+) early-stage breast cancer for 10 years of endocrine therapy","volume":"27","author":"Noordhoek","year":"2021","journal-title":"Clin Cancer Res"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977626000482?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977626000482?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T07:23:03Z","timestamp":1778570583000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960977626000482"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":34,"alternative-id":["S0960977626000482"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2026.104738","relation":{},"ISSN":["0960-9776"],"issn-type":[{"value":"0960-9776","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Late distant recurrence prediction model in premenopausal women with ER-positive\/HER 2-negative breast cancer: A multicenter retrospective study","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2026.104738","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104738"}}